Dipeptidyl peptidase IV (CD26) activity in human alloreacyive T cell subsets varies with the stage of differentiation and activation status

Transplant Immunology

Volumn 5, Issue 2, 1997, Pages 152-161

  Ruiz, Phillip ^a   Hao, Lei ^a   Zucker, Keith ^a   Zacharievich, Natalia ^a   Viciana, Ana L ^a   Shenkin, Mark ^b   Miller, Joshua ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b BECKMAN COULTER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; PADGEM PROTEIN; RHODAMINE 110;

ALLOIMMUNITY; ANTIGEN EXPRESSION; ARTICLE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LYMPHOCYTE DIFFERENTIATION; MIXED LYMPHOCYTE REACTION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

EID: 0030789545     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-3274(97)80056-1     Document Type: Article

References (57)

1. Ulmer A, Mattern T, Feller A, Heymann E, Flad HD. CD26 antigen is a surface dipeptidyl peptidase IV (DPP IV) as characterized by monoclonal antibodies clone TII-19-4-7 and 4EL1C7. Scand J Immunol 1990; 31: 429-35.
2. De Meester I, Vanhoof G, Hendriks D, Demuth HU, Yaron A, Scarpe S. Characterization of dipeptidyl peptidase IV (CD26) from human lymphocytes. Clin Chim Acta 1992; 210: 23-34.
3. Shipp MA, Look AL. Hematopoietic differentiation antigens that are membrane associated enzymes: cutting is the key! Blood 1993; 82: 1052-70.
4. Abbott CA, Baker E, Sutherland GR, McCaughan GW. Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene. Immunogenetics 1994; 40: 331-38.
5. Walter R, Simmons WH, Yoshimoto T. Proline specific endo-and exopeptidases. Mol Cell Biochem 1980; 30: 111-27.
6. Mattern T, Reich C, Duchrow M, Ansorge S, Ulmer AJ, Flad HD. Antibody-induced modulation of CD26 surface expression. Immunology 1995; 84: 595-600.
7. Naquet P, Vivier I, Gorvel JP et al. Activation of mouse T lymphocytes by a monoclonal antibody to a developmentally regulated surface aminopeptidase. Immunol Rev 1989; 111: 177-93.
8. Shimizu Y, Shaw S. Lymphocyte interactions with extracellular matrix. FASEB J 1991; 5: 2292-99.
9. Kameoka J, Tanaka T, Nojima Y, Schlossman SF, Morimoto C. Direct association of adenosine deaminase with a T cell activation antigen CD26. Science 1993; 261: 466-69.
10. Torimoto Y, Dang NH, Vivier E, Tanaka T, Schlossman SF, Morimoto C. Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes. J Immunol 1991; 147: 2514-17.
11. Schon E, Jahn S, Kiessig HU et al. The role of dipeptidyl peptidase IV in human T lymphocyte activation inhibitors and antibodies against dipeptidyl peptidase IV suppress lymphocyte proliferation and immunoglobulin synthesis in vitro. Eur J Immunol 1987; 17: 1821-26.
12. Buhling F, Junker U, Reinhold D, Neubert K, Jager L, Ansorge S. Functional role of CD26 on human B lymphocytes. Immunol Lett 1995; 45: 47-51.
13. Buhling F, Dunz D, Reinhold D et al. Expression and functional role of dipeptidyl peptidase IV on human natural killer cells. Nat Immun 1994; 13: 270-79.
14. Kameoka J, Sato T, Torimoto Y et al. Differential CD26-mediated activation of the CD3 and CD2 pathways after CD6-depleted allogeneic bone marrow transplantation. Blood 1995; 85: 1132-37.
15. Vanham G, Kesterns L, De Meester L et al. Decreased expression of the memory marker CD26 on both CD4(+) and CD8(+) T lymphocytes of HIV infected subjects. J Acquir Immune Defic Syndr 1993; 6: 749-57.
16. Martin M, Huguet J, Centelles JJ, Franco R. Expression of Ecto-Adenosine deaminase and CD26 in human T cells triggered by the TCR-CD3 complex. J Immunol 1995; 155: 4630-43.
17. Dang NH, Torimoto Y, Deusch K, Schlossman SF, Morimoto C. Comitogenic effect of solid phase immunobilized anti-IF7 on human CD4 T cell activation via CD3 and CD2 pathways. J Immunol 1990; 144: 4092-100.
18. Bednarczyk J, Carroll SM, Marin C, McIntyre B. Triggering of the proteinase dipeptidyl peptidase IV (CD26) amplifies human T lymphocyte proliferation. J Cell Biochem 1991; 46: 206-18.
19. Ruiz P, Nassiri M, Steele B, Viciana AL. Cytofluorographic evidence that thymocyte dipeptidyl peptidase IV (CD26) activity is altered with stage of ontogeny and apoptotic status. Cytometry 1996; 23: 322-29.
20. Bauvois B. Murine thymocytes possess specific cell surface-associated exoaminopeptidase activities: preferential expression by immature CD4-CD8-subpopulation. Eur J Immunol 1990; 20: 459-68.
21. Tanaka T; Kameoka J, Yaron A, Schlossman SF, Morimoto C. The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. Proc Natl Acad Sci USA 1993; 90: 4586-90.
22. De Meester IA, Kestens LL, Vanham GL et al. Costimulation of CD4+ and CD8+ T cells through CD26: the ADA-binding epitope is not essential for complete signaling. J Leukoc Biol 1995; 58: 325-30.
23. Muscat C, Bertotto A, Agea E et al. Expression and functional role of 1F7 (CD26) antigen on peripheral blood and synovial fluid T cells in rheumatoid arthritis patients. Clin Exp Immunol 1994; 98: 252-56.
24. Scheel-Toellner D, Richter E, Toellner KM et al. CD26 expression in leprosy and other granulomatous diseases correlates with the production of interferon-y. Lab Invest 1995; 73: 685-90.
25. Van Leer EHG, Bruijin JA, Prins FA, Hoedemaeker PJ, De Heer F. Redistribution of glomerular dipeptidyl peptidase type IV in experimental lupus nephritis. Lab Invest 1993; 68: 550-56.
26. Callebaut C, Krust B, Jacotot E, Hovanessian AG. T cell activation antigen, CD26 as a cofactor for entry of HIV in CD4+ cells. Science 1993; 262: 2045-50.
27. West WHL, Stott EJ. Cell surface expression of CD26 does not correlate with susceptibility to immunodeficiency viruses. AIDS 1994; 8: 1349-51.
28. Werner A, Mattern T, Ulmer AJ, Flad HD, Kurth R, Maier M. CD26 is not required for infection of the lymphoma cell line C8166 with HIV-1. AIDS 1994; 8: 1348-49.
29. Masuyama JI, Berman JS, Cruikshank WW, Morimoto C, Center DM. Evidence for recent as well as long term activation of T cells migrating through endothelial cell monolayers in vitro. J Immunol 1992; 148: 1367-74.
30. Duke-Cohan JS, Morimoto C, Rocker JA, Schlossman SF. A novel form of dipeptidyl peptidase IV found in human serum: isolation, characterization, and comparison with T lymphocyte membrane dipeptidyl peptidase IV (CD26). J Biol Chem 1995; 270: 14107-14.
31. Sanda MG, Pierson R, Smith C, Reemtsma K, Rose E. Serum Dipeptidyl Peptidase IV in cardiac transplant recipients. Transplant Proc 1989; 21: 2525-26.
32. Leytus SP, Patterson WL, Mangel WF. New class of sensitive and selective fluorogenic substrates for serine proteinases. Biochem J 1983; 215: 253-60.
33. Assfalg-Machleidt I, Rothe G, Klingel S et al. Membrane permeable fluorogenic rhodamine substrates for selective determination of cathepsin L. Biol Chem Hoppe-Seyler 1992; 373: 433-40.
34. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand J Lab Clin Invest 1968; 21: 77-89.
35. Rosen-Bronson S, Johnson AH, Hartzman RJ, Eckels DD. Human allospecific TLCs generated against HLA antigens associated with DR1 through DRw8: growth and specificity analysis. Immunogenetics 1986; 24: 368-78.
36. Ruiz P, Streilein JW. Evidence that I-E-negative mice resistant to neonatal H-2 tolerance induction display ubiquitous thymic clonal deletion of donor-reactive T cells. Transplantation 1993; 55: 321-28.
37. Ruiz P, Coffman TM, Howell DN et al. Evidence that pretransplant donor blood transfusion prevents rat renal allograft dysfunction but not the in situ cellular alloimmune or morphologic manifestations of rejection. Transplantation 1988; 45: 1-7.
38. Nilsson K, Klein G. Phenotypic and cytogenetic characteristics of human B lymphoid cell lines and their relevance for the etiology of Burkitt's lymphoma. Adv Cancer Res 1982; 37: 319-80.
39. Panzara MA, Gussoni E, Steinman L, Oksenberg JR. Analysis of the T cell repertoire using the PCR and specific oligonucleotide primers. Biotechniques 1992; 12: 728-35.
40. Charley M, McCoy JP, Deng JS, Jegesothy B. Anti-V region antibodies as ÔAlmost Clonotypic' reagents for the study of cutaneous T cell lymphomas and leukemias. J Invest Dermatol 1995; 95: 614-17.
41. Nassiri M, Viciana A, Streilein JW, Ruiz P. Donor-specific skin transplants activate allodestructive T cells in mice resistant to neonatal H-2 tolerance induction. Transplantation 1993; 56: 1460-67.
42. Ruiz P, Nassiri M, Viciana AL, Padmanabhan J, Streilein JW. Characterization of donor chimerism, alloreactive host T cells and memory cell development in thymi from mice resistant to neonatal transplantation tolerance. J Immunol 1995; 154: 633-43.
43. Budd RC, Cerottini JC, Horvath C et al. Distinction of virgin and memory T lymphocytes: stable acquisition of the Pgp-1 glycoprotein concomitant with antigenic stimulation. J Immunol 1987; 138: 3120-29.
44. Lechler RI, Lombardi G, Batchelor JR, Reinsmoen N, Bach FH. The molecular basis of alloreactivity. Immunol Today 1990; 11: 83-89.
45. Hutchinson IV. Cellular mechanisms of allograft rejection. Curr Opin Immunol 1991; 3: 722-28.
46. Di Stefano JF, Beck G, Lane B, Zucker S. Role of tumor cell membrane-bound serine proteases in tumor-induced target cytolysis. Cancer Res 1982; 42: 207-18.
47. Frank, MM, Fries LF. The role of complement in inflammation and phagocytosis. Immunol Today 1991; 12: 321-26.
48. Scholz W, Mentlein R, Heymann E, Feller AC, Ulmer AJ, Flad HD. Interleukin 2 production by human T lymphocytes identified by antibodies to Dipeptidyl Peptidase IV. Cell Immunol 1985; 93: 199-211.
49. Mundy DI, Strittmatter WJ. Requirement for metalloendoprotease in exocytosis. Evidence in mast cells and adrenal chromaffin cells. Cell 1985; 40: 645-56.
50. Alhanaty E, Shaltiel S. Limited proteolysis of the catalytic subunit of cAMP-dependent protein kinase: A membranal regulatory device656. Biochem Biophys Res Commun 1979; 89: 323-32.
51. Morimoto C, Schlossman SF. CD26: a key costimulatory molecule on CD4 memory T cells. Immunologist 1994; 2: 4-7.
52. Fukiwara H, Fukuoka M, Yasuda K et al. Cytokines stimulate dipeptidyl peptidase-IV expression on human luteinizing granulosa cells. J Clin Endocrinol Metab 1994; 79: 1007-11.
53. Morimoto C, Torimoto Y, Levison G et al. 1F7, a novel cell surface molecule involved in helper function of CD4 cells. J Immunol 1989; 143: 3430-39.
54. Dang NH, Torimoto Y, Schlossman SF, Morimoto C. Human CD4 helper T cell activation: functional involvement of two distinct collogen receptor IF7 and VLA integrin family. J Exp Med 1990; 172: 649-52.
55. Droz D, Zachar D, Charbit L, Gogusev Chretien JY, Iris L. Expression of human nephron differentiation molecules in renal cell carcinoma. Am J Pathol 1990; 137: 895-905.
56. Reinhold D, Bank U, Buhling F et al. Inhibitors of Dipeptidyl Peptidase IV (DP IV, CD26) specifically suppress proliferation and modulate cytokine production of strongly CD26 expressing U937 cells. Immunobiology 1994; 192: 121-36.
57. Hu W, Weyand CM, Goronzy JJ. The T-cell receptor Vβ6 gene usage in alloreactive T-cell responses. Human Immunol 1995; 42: 72-80.